Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 686.71

+1.7%

10:38 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: CuttingEdge Bio who wrote (2863)	3/22/2020 11:08:22 PM
From: Miljenko Zuanic	of 3557

<This was a ph1 in healthy volunteers, so what was there to report?. How about PD/PK parameters? Safety profile? Tolerance? Distribution? Tissue penetration?... < It would seem that perhaps penetration of drug to the lung is the main hurdle. I wonder how they addressed this or plan to address this with Wuhan.> That, or maybe once SARS-viral load is passing certain threshold, Abs on its own can do so much! In regards early post reply, I can only said that nCoV is nasty virus (with way unusual mutation that enhance its VIRAL property), and that cocktail need to be specifically directed as to each Ab-component enhance other one. For Ebolas they did run primate LIVE study, and there they observed enhanced antiviral activity. Will they have time to do the same for nCoV, or after pressed by certain entity...skip certain part in development? In primate study they observed post-exposure therapeutic potential. Believe me, for the sake of the many that will suffer under current outbreak, I wish that they may have even better success.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next